about
Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated MalignanciesChimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Human Papillomavirus E2 Protein: Linking Replication, Transcription, and RNA Processing.Human papillomavirus type 18 infection in a female renal allograft recipient: a case report.HPV disease transmission protection and control.Recent advances in understanding and preventing human papillomavirus-related disease.Prognostic variables in high-risk cutaneous squamous cell carcinoma: a review.The interaction between human papillomavirus and other viruses.Successful improvement of Buschke-Löwenstein tumour in an HIV-infected patient with antiretroviral therapy alone.ASSOCIATION OF EPSTEIN-BARR VIRUS (EBV) BUT NOT HUMAN PAPILLOMAVIRUS (HPV) WITH GINGIVITIS AND/OR PERIODONTITIS IN TRANSPLANTED INDIVIDUALS.Efficacy of fulguration combined with imiquimod cream on condyloma acuminatum, and the effect on immune functions and serums levels of IL-2 and IL-10.Incomplete vaccination coverage in European children with end-stage kidney disease prior to renal transplantation.Human papillomavirus-associated cutaneous disease burden in human immunodeficiency virus (HIV)-positive patients: the role of human papillomavirus vaccination and a review of the literature.Development of an in vivo infection model to study Mouse papillomavirus-1 (MmuPV1).HPV vaccination of immunocompromised hosts.Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study.Eponychial lesions following bilateral upper extremity vascular composite allotransplantation: a case report.Everolimus and papillomavirus lesions in female renal transplant recipient: A case report.
P2860
Q26770541-AB41AF4A-04DE-472A-ABC0-4932C76F56F5Q36240497-4AA72450-711C-4272-9210-1E898FF57ED2Q37252986-75D666EE-5ED1-4B51-BCB9-0EDDEA66DAC6Q37402887-B39C3823-1D10-4372-AF4A-C83F317695EEQ37705703-706387FE-21A1-4D13-9DC1-0BBBFDAC333FQ37709706-9155EE0C-BAB3-45C8-A043-22AFEC0F5AA1Q38893927-DA2AAC6C-3D02-4AFB-AE94-A77F4F7B565DQ39003290-AD0B7B47-122C-4034-97F3-462B92724D5CQ40441636-E2C2E28F-98F1-4B27-B936-D92DE1FB74FAQ40615071-E256FBCD-157E-43C6-8FFB-40116063D446Q41017220-9CFFCE48-DDE8-4974-8A1D-F231CD719CA5Q41923147-2D926A16-37FD-4665-BABE-104494CBD647Q45324643-7C0F602A-D9A7-4B07-B523-93E763964421Q46237480-7C72A811-8360-47CB-A2F9-BC398AE25CE9Q46355059-A3E8D38D-C64B-433B-8114-A58360CA5CE8Q48102349-22AED638-0EEA-4BAD-96B9-BE63FFECE476Q49262749-60E7D54F-C557-48EC-9D85-3AB5E029EBCBQ55248930-EB92C52E-AA9F-430E-BAB2-C3D966E249B9
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
HPV Carcinomas in Immunocompromised Patients
@ast
HPV Carcinomas in Immunocompromised Patients
@en
HPV Carcinomas in Immunocompromised Patients
@nl
type
label
HPV Carcinomas in Immunocompromised Patients
@ast
HPV Carcinomas in Immunocompromised Patients
@en
HPV Carcinomas in Immunocompromised Patients
@nl
prefLabel
HPV Carcinomas in Immunocompromised Patients
@ast
HPV Carcinomas in Immunocompromised Patients
@en
HPV Carcinomas in Immunocompromised Patients
@nl
P2093
P2860
P3181
P356
P1476
HPV Carcinomas in Immunocompromised Patients
@en
P2093
Christopher Downing
Jacqueline Guidry
Nicole M Reusser
Stephen K Tyring
P2860
P304
P3181
P356
10.3390/JCM4020260
P407
P577
2015-01-01T00:00:00Z